P-408 - TIME OF TREATMENT NEEDED IN A PUBLIC RADIATION ONCOLOGY DEPARTMENT
P-409 - TIMING OF A PRIVATE RADIATION ONCOLOGY DEPARTMENT
P-410 - TOLERANCE AND CONTROL IN SKULL-BASE CHORDOMAS WITH PROTONTHERAPY: EARLY OUTCOMES
P-411 - TOLERANCE AND EFFICACY OF APALUTAMIDE; PRELIMINARY RESULTS IN OUR CENTRE
P-412 - TOLERANCE OF EXTREME HYPOFRACTIONATED BREAST IRRADIATION
P-413 - TOLERANCE OF EXTREME HYPOFRACTIONATION ON THE PRIMARY TUMOR IN MHSPC
P-414 - TOTAL BODY IRRADIATION (TBI): RESULTS OF 10GY IN 3-DAYS FRACTIONATION
P-415 - TOTAL NEOADJUVANT THERAPY (RAPIDO) IN RECTAL CANCER MANAGEMENT, OUR EXPERIENCE.
P-416 - TOXICIDAD CUTÁNEA NO RELACIONADA CON RADIOTERAPIA EN CÁNCER DE MAMA
P-417 - TOXICITY AND DOSIMETRY ACCORDING TO POSITIONING IN MAMA FAST
P-418 - TOXICITY ASSESSMENT OF POSTOPERATIVE VMAT RADIOTHERAPY FOR LUNG CANCER
P-419 - TOXICITY, COSMETIC AND ONCOLOGIC COMPARISON BETWEEN ACCELERATED-MINIMAL-BREAST-IRRADIATION(AMBI) VERSUS 4-FRACTIONS AMBI(4F-AMBI).
P-420 - TRATAMIENTO TSI (IRRADIACIÓN CUTÁNEA TOTAL CON ELECTRONES) EN LESIONES PROFUNDAS
P-421 - TREATMENT OF CORDOMAS WITH PROTON THERAPY: FIRST EXPERIENCE IN SPAIN
P-422 - TREATMENT OF RECURRENT KELOIDS WITH HIGH DOSE RATE BRACHYTHERAPY
P-423 - TREATMENT WITH FRACTIONED STEREOTACTIC RADIOTHERAPY (RTEF) IN SINGLE BRAINSTEM METASTASES.
P-424 - TREATMENT-RELATED ADVERSE EVENTS WITH APALUTAMIDE IN PROSTATE CANCER
P-425 - TRENDS USING LUNG STEREOTACTIC BODY RADIOTHERAPY (SBRT): 5-YEAR EXPERIENCE
P-426 - TRIMODALITY TREATMENT FOR MUSCLE-INVASIVE BLADDER CANCER
P-427 - T-score evaluation as prognostic factor in locally advanced cervical cancer
P-428 - TUMOUR RADIOSENSITIZATION MEDIATED BY PX478, A HYPOXIA-INDUCIBLE FACTOR 1-ALPHA INHIBITOR